Phase II open-label study of sunitinib in patients with advanced breast cancer. - Wikidata - wikimedia - TriplyDB

Phase II open-label study of sunitinib in patients with advanced breast cancer.

Phase II open-label study of sunitinib in patients with advanced breast cancer.

http://www.wikidata.org/entity/Q33403848

about

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history.Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.

P2860

Q33413742-ECFE782C-9B3F-47A2-A4FE-1469722302E1 Q35695381-287FBE9C-7C9D-495E-AC08-0D600A3A0E9E Q37133927-C84DD368-7111-454A-98DC-8F7BE2AFF3EA Q37214094-47A0D64D-1084-49DD-B9D3-34F40DC43B3E Q37707145-397513BB-10B5-49B0-B2BC-41D8F1BFDD60 Q38193533-79255C25-434A-43E5-BC5B-1ED9DA8FDE1F Q38627885-F878F179-7D42-4B8F-A739-27E0673F51FE Q47339196-57209197-CAC0-4EAC-920A-52BF456CECE1 Q54393339-F1FA14C7-16D7-40AA-B447-444B20587F6E

P2860

Phase II open-label study of sunitinib in patients with advanced breast cancer.

http://www.wikidata.org/entity/Q33403848

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@ast

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@en

type

label

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@ast

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@en

prefLabel

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@ast

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@en

P1433

Q33403848-CC50A1A2-0CA7-4898-B5BF-C30B7514904B

P1476

Q33403848-2443B597-6127-4C72-A981-9251E381201B

P2093

Q33403848-304DD866-BBAF-4E66-9E72-DF3B5053CE6D

Q33403848-358020FC-3CE7-4C72-83FC-7541578C0025

Q33403848-4A359667-C3E9-4C0F-92D9-0762896D7A2F

Q33403848-605B81E5-85E9-4C5C-B209-8552C109BF43

Q33403848-6A6428C2-106D-479E-8FF4-85B7229FD5F9

Q33403848-9C8D9721-5505-4A67-BE3C-12B06091C893

Q33403848-B50AA675-C194-44E8-A8E0-4F4BDC39F1C0

Q33403848-CB34FE9E-AAAD-4D24-96C0-79376BFB259B

Q33403848-DFB34778-4AAC-440D-B94F-8CCB5E52F9FA

Q33403848-F418196E-D618-412E-9DCC-FBF39ECA5C6D

P2860

Q33403848-07DF2CF3-7B4A-418C-AF87-C9831CAF45DF

Q33403848-0BE43F3F-C63C-4B0E-A6FA-983ACBF0EE3C

Q33403848-194C33CA-6D0F-47F0-BA68-BF91E1E37480

Q33403848-4664AA37-2D2D-41D4-ABB0-3E5586A6100B

Q33403848-48ECC6A8-972B-4408-BDED-1AC28D95BB5E

Q33403848-4BDE17E2-F62B-4E16-A6A0-5937BA3E9E21

Q33403848-4DF0E32C-AB4D-42CA-B0D2-EC80BD879F31

Q33403848-7303E1CC-C8DA-4EF9-94ED-1B739BC34BBA

Q33403848-77A2459A-42EF-4908-96AA-F55B5F278652

Q33403848-7EFB7C8E-4477-4607-9B98-59B4B75B5CBF

P2888

Q33403848-33ADDDB5-0885-4DA6-8CF2-9E4A9C94375F

P304

Q33403848-15FA3FD8-0F2F-4B28-A1DF-701A6705B5B5

P31

Q33403848-24C62ED3-92DC-4175-A67E-D436B9E39BF7

P356

Q33403848-BAFCAC62-7616-422B-AA7F-8A7F21983CBE

P407

Q33403848-8F08DF74-01DB-4249-8138-28F9F0AA21BE

P433

Q33403848-EAFAC14B-EA72-4AAB-B356-8165E9F6D468

P478

Q33403848-81BFC7EB-2238-41AF-87D8-A0BB1F575960

P577

Q33403848-9E5569D2-B179-42AF-AF95-BC7EF5E84936

P6179

Q33403848-6EC12E6C-935C-40BF-B960-9C199836DA5B

P698

Q33403848-A9461A18-D1AD-40DC-AF49-56B128D3C0E6

P356

S10549-012-2285-0

P1433

Breast Cancer Research and Treatment

P1476

Phase II open-label study of sunitinib in patients with advanced breast cancer.

@en

P2093

Denise A Yardley

http://www.w3.org/2001/XMLSchema#string

Dennis L Citrin

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Jolanda Paolini

http://www.w3.org/2001/XMLSchema#string

Kenneth A Kern

http://www.w3.org/2001/XMLSchema#string

Marla J Brickman

http://www.w3.org/2001/XMLSchema#string

Paul Healey

http://www.w3.org/2001/XMLSchema#string

Sherry Li

http://www.w3.org/2001/XMLSchema#string

Stephen D Myers

http://www.w3.org/2001/XMLSchema#string

Zhixiao Wang

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

P2888

s10549-012-2285-0

P304

759-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2285-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033335591

http://www.w3.org/2001/XMLSchema#string

P698

23073758

http://www.w3.org/2001/XMLSchema#string